Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes

被引:17
作者
Kudo, Toshiyuki [1 ]
Ozaki, Yuya [1 ]
Kusano, Tomomi [1 ]
Hotta, Eri [1 ]
Oya, Yuka [1 ]
Komatsu, Seina [1 ]
Goda, Hitomi [1 ]
Ito, Kiyomi [1 ]
机构
[1] Musashino Univ, Pharmaceut Sci Res Inst, 1-1-20 Shinmachi, Nishitokyo, Tokyo 2028585, Japan
基金
日本学术振兴会;
关键词
CYP2C8; CYP3A4; human liver microsomes; paclitaxel; Phosphate buffer; triazolam; Tris-HCl buffer; CONFORMATIONAL-CHANGE; PLASMA-CONCENTRATIONS; DRUG-METABOLISM; REPAGLINIDE; BIOTRANSFORMATION; PHARMACOKINETICS; MIDAZOLAM; CYP2C8; CYP3A; TESTOSTERONE;
D O I
10.3109/00498254.2015.1071502
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1.Buffer conditions in in vitro metabolism studies using human liver microsomes (HLM) have been reported to affect the metabolic activities of several cytochrome P450 (CYP) isozymes in different ways, although there are no reports about the dependence of CYP2C8 activity on buffer conditions.2.The present study investigated the effect of buffer components (phosphate or Tris-HCl) and their concentration (10-200mM) on the CYP2C8 and CYP3A4 activities of HLM, using paclitaxel and triazolam, respectively, as marker substrates.3.The K-m (or S-50) and V-max values for both paclitaxel 6-hydroxylation and triazolam - and 4-hydroxylation, estimated by fitting analyses based on the Michaelis-Menten or Hill equation, greatly depended on the buffer components and their concentration.4.The CLint values in phosphate buffer were 1.2-3.0-fold (paclitaxel) or 3.1-6.4-fold (triazolam) higher than in Tris-HCl buffer at 50-100mM. These values also depended on the buffer concentration, with a maximum 2.3-fold difference observed between 50 and 100mM which are both commonly used in drug metabolism studies.5.These findings suggest the necessity for optimization of the buffer conditions in the quantitative evaluation of metabolic clearances, such as in vitro-in vivo extrapolation and also estimating the contribution of a particular enzyme in drug metabolism.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 23 条
  • [1] CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
    Bidstrup, TB
    Bjornsdottir, I
    Sidelmann, UG
    Thomsen, MS
    Hansen, KT
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (03) : 305 - 314
  • [2] Busby WF, 1999, DRUG METAB DISPOS, V27, P246
  • [3] Crespi CL., 1998, EFFECT SALT CONCENTR
  • [4] PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS
    DAVIES, B
    MORRIS, T
    [J]. PHARMACEUTICAL RESEARCH, 1993, 10 (07) : 1093 - 1095
  • [5] EBERTS FS, 1981, CLIN PHARMACOL THER, V29, P81, DOI 10.1038/clpt.1981.14
  • [6] Houston JB, 2000, DRUG METAB DISPOS, V28, P246
  • [7] Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
    Iwatsubo, T
    Hirota, N
    Ooie, T
    Suzuki, H
    Shimada, N
    Chiba, K
    Ishizaki, T
    Green, CE
    Tyson, CA
    Sugiyama, Y
    [J]. PHARMACOLOGY & THERAPEUTICS, 1997, 73 (02) : 147 - 171
  • [8] Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast
    Karonen, T.
    Filppula, A.
    Laitila, J.
    Niemi, M.
    Neuvonen, P. J.
    Backman, J. T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 223 - 230
  • [9] Maenpaa J, 1998, PHARMACOGENETICS, V8, P137
  • [10] Mück W, 2000, CLIN PHARMACOKINET, V39, P99